ArticleOncogene2016
N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Aerosol-Derived Graphene Oxide Nanofilm Suppresses Adhesion-Dependent Survival and Migration in Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2026Article
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Effects of sesamin on the chemosensitivity, invasiveness and immune evasion mechanism of human lung adenocarcinoma.International journal of molecular medicine · 2025Article
- Article
- Biomarkers for Prostate Cancer Aggressiveness in Puerto Rican Men: Analysis of Phospho-Rb S249, N-cadherin, β-catenin, and E-cadherin Expression in Prostate Biopsies.Ponce Health Sciences University scientific journal · 2025Article
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non-canonical WNT pathway (FYN/STAT3).Clinical and translational medicine · 2023Article
- Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.Endocrine · 2022Article
- Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.Cell communication and signaling : CCS · 2022Article
- Disentangling cadherin-mediated cell-cell interactions in collective cancer cell migration.Biophysical journal · 2022Article
- Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.Journal of hematology & oncology · 2021Review
- N-cadherin in osteolineage cells modulates stromal support of tumor growth.Journal of bone oncology · 2021Article
- Targeting TRAF3IP2, Compared to Rab27, is More Effective in Suppressing the Development and Metastasis of Breast Cancer.Scientific reports · 2020Article
- Review
- Tumor-Derived Exosomes Mediate the Instability of Cadherins and Promote Tumor Progression.International journal of molecular sciences · 2019Review
- N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.BMC cancer · 2018Review
- Novel Methylselenoesters Induce Programed Cell Death via Entosis in Pancreatic Cancer Cells.International journal of molecular sciences · 2018Article
- Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.British journal of cancer · 2018Article
- ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.Cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Cadherin subtype switching from E-cadherin to N-cadherin is associated with the epithelial-to-mesenchymal transition (EMT), a process required for invasion and dissemination of carcinoma cells. We found that N-cadherin is expressed in human and mouse pancreatic intraepithelial neoplasia (PanIN), suggesting that N-cadherin may also have a role in early-stage pancreatic cancer. To investigate the role of N-cadherin in mouse PanIN (mPanIN), we simultaneously activated oncogenic K-ras(G12D) and deleted the N-cadherin (Cdh2) gene in the murine pancreas. Genetic ablation of N-cadherin (N-cad KO) caused hyperproliferation, accelerated mPanIN progression, and early tumor development in K-ras(G12D) mice. Decreased E-cadherin and redistribution of β-catenin accompanied the loss of N-cadherin in pancreatic ductal epithelial cells (PDEC). Nuclear accumulation of β-catenin and its transcription co-activator Tcf4 led to activation of Wnt/β-catenin target genes. Unexpectedly, loss of N-cadherin in the K-ras(G12D) model resulted in increased mPanIN progression and tumor incidence. These in vivo results demonstrate for the first time that N-cadherin functions as a growth suppressor in the context of oncogenic K-ras.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.